Summary of longitudinal research program
Khavinson Epithalon/Epithalamin Longevity Research Overview — VialBase Research
15+ years of human studies with epithalamin/epitalon in elderly patients
Last updated · 2002-2020 · Khavinson VK, Morozov VG · Various (Neuro Endocrinol Lett, other Russian journals)
Key findings
- 15+ years of human studies with epithalamin/epitalon in elderly patients
- Improved biomarkers of aging including melatonin restoration
- Rat lifespan extension studies showed increased median and maximum lifespan
- Pineal peptide bioregulation theory: short peptides interact directly with DNA
- Over 200 publications from Khavinson's group on peptide bioregulation
Khavinson’s Epithalon Longevity Research Program
Background
Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology has been the primary researcher behind epithalon for 35+ years. His work on “peptide bioregulation” posits that short peptides (2-4 amino acids) can interact directly with DNA to modulate gene expression.
Key Findings Across Program
- Rat Lifespan: Epithalamin (natural pineal extract, precursor to synthetic epitalon) extended both median and maximum lifespan in rats
- Human Geriatric Studies: 15+ year follow-up of elderly patients receiving epithalamin showed improved biomarkers
- Melatonin Restoration: Elderly patients showed normalized melatonin rhythms after epithalon treatment
- Telomerase Activation: Epithalon activated telomerase in human somatic cells in vitro
- Pineal Gland Function: Epithalon counteracted age-related pineal calcification effects
Limitations
- Most research published in Russian journals with limited peer review in Western literature
- Study designs often lack the rigor expected by FDA standards
- Confounding variables in longitudinal human studies
- Mechanism of direct peptide-DNA interaction remains controversial
Relevance
Provides the foundational evidence base for Epithalon use in longevity protocols. While the evidence quality is mixed, the consistency across 35 years of research and the recent Western validation of telomerase activation (PMID: 40908429) lend credibility to the core claims.